Criteria for Preservative Free (PF) and Single Dose Unit (SDU) presentations:
These are restricted to patients with • true preservative allergy and/or • evidence of epithelial toxicity from preservatives and/or • severe dry eyes and/or • require/ may require surgery in the near future and/or • neonates
Antioxidants and Multivitamins for Age Related Macular Degeneration
Administration of drugs to the eye
Control of microbial contamination
Anti-infective eye preparations
Amber £££ 2nd line
Use SDU if using 1or 2 hourly or if significant OSD/toxicity.
Not for new patients, existing patients to remain on treatment.
Timolol 0.5% single dose units
Timolol LA 0.5% Eye Drops
Not for new patients
Existing patients to remain on treatment
Timolol Once-daily (Nyogel®)
Tissue Adhesive (Histacryl®)
Total Care Daily Cleaner
Total Care Disinfecting and Wetting Solution
Travoprost with Timolol (DuoTrav®)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
High Cost Medicine
Cancer Drugs Fund
Traffic Light Status Information
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.
Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.
Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.
Medicines for initiation and maintenance prescribing by Specialists only
Non-formulary medicines- medicines not recommended for routine primary care prescribing.
Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.